Ulinastatin enhances the therapeutic effect of intraperitoneal lavage on severe acute pancreatitis in rats

Feng,Cong; Su,Xuan; Chen,Li; Zhou,Xuan; Li,Bei; Wang,Li‑Li; Lv,Fa‑Qin; Li,Tan‑Shi

doi:10.3892/etm.2015.2334

Ulinastatin enhances the therapeutic effect of intraperitoneal lavage on severe acute pancreatitis in rats

Authors:
- Cong Feng
- Xuan Su
- Li Chen
- Xuan Zhou
- Bei Li
- Li‑Li Wang
- Fa‑Qin Lv
- Tan‑Shi Li
View Affiliations

Affiliations: Department of Emergency, General Hospital of the PLA, Beijing 100853, P.R. China, Department of Hepatology‑Immunology, Beijing Youan Hospital of the Capital Medical University, Beijing 100069, P.R. China, Department of Ultrasound, General Hospital of the PLA, Beijing 100853, P.R. China
Published online on: March 9, 2015 https://doi.org/10.3892/etm.2015.2334
Pages: 1651-1655
Copyright: © Feng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the therapeutic effect of peritoneal lavage with ulinastatin on the outcome of rats with severe acute pancreatitis (SAP). A total of 110 male Wistar rats were randomly divided into the following groups: Control (C), SAP model (SAP), saline lavage (SL), intravenous ulinastatin (IU) and low‑dose (LUL), medium‑dose (MUL), high‑dose (HUL) and ultrahigh‑dose (UHUL) ulinastatin lavage. The treatments were performed immediately subsequent to the establishment of the SAP model. Intraperitoneal lavage with or without ulinastatin was performed for 3 h. Survival time was recorded for 12 h and the median survival time was calculated. Histopathological analyses, and measurements of plasma amylase and lipase levels were performed. Blood pH, lactic acid and base excess were also detected. The LUL, MUL, HUL, UHUL and IU groups showed an increase in the median survival time compared with the SAP group, with the maximal effect observed in the MUL group (P<0.01). The SL, MUL and IU groups showed a reduced activity of amylase and lipase compared with the SAP group. The SL (P<0.01) and the MUL groups (P<0.01) additionally showed a reduction in the lactic acid in arterial blood relative to the SAP group but the IU group did not. The MUL group showed greater improvements in pH (P<0.01) and base excess (P<0.01) versus the SAP group than the SL and IU groups. Furthermore the MUL group demonstrated a more marked reduction in the histological changes in necrosis, edema and inflammation compared with the SL and IU groups. Intraperitoneal lavage with ulinastatin significantly improves the prognosis of SAP in rats.

View Figures

View References

1	Niederau C, Crass RA, Silver G, Ferrell LD and Grendell JH: Therapeutic regimens in acute experimental hemorrhagic pancreatitis. Effects of hydration, oxygenation, peritoneal lavage, and a potent protease inhibitor. Gastroenterology. Gastroenterology. 95:1648–1657. 1988.PubMed/NCBI
2	Wilson C and Imrie CW: Effective intraperitoneal antiprotease therapy for taurocholate-induced pancreatitis in rats. Br J Surg. 77:1252–1255. 1990. View Article : Google Scholar : PubMed/NCBI
3	Fric P, Slabý J, Kasafírek E, Kocna P and Marek J: Effective peritoneal therapy of acute pancreatitis in the rat with glutaryl-trialanin-ethylamide: a novel inhibitor of pancreatic elastase. Gut. 33:701–706. 1992. View Article : Google Scholar : PubMed/NCBI
4	Leonhardt U, Seidensticker F, Fussek M, Stöckmann F and Creutzfeldt W: Camostate (FOY-305) improves the therapeutic effect of peritoneal lavage on taurocholate induced pancreatitis. Gut. 31:934–937. 1990. View Article : Google Scholar : PubMed/NCBI
5	Ohnishi H, Kosuzume H, Ashida Y, Kato K and Honjo I: Effects of urinary trypsin inhibitor on pancreatic enzymes and experimental acute pancreatitis. Dig Dis Sci. 29:26–32. 1984. View Article : Google Scholar : PubMed/NCBI
6	Tani S, Otsuki M, Itoh H, et al: The protective effect of the trypsin inhibitor urinastatin on cerulein-induced acute pancreatitis in rats. Pancreas. 3:471–476. 1988. View Article : Google Scholar : PubMed/NCBI
7	Inoue K, Takano H, Shimada A, et al: Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol. 67:673–680. 2005. View Article : Google Scholar : PubMed/NCBI
8	Li F, Zhang H, Xu KY, Wei Q and Zhou GX: Role of the chemokine fractalkine in a rat model of acute necrotizing pancreatitis and the interventional effect of ulinastatin. Arch Iran Med. 16:83–87. 2013.PubMed/NCBI
9	Inoue K, Takano H, Shimada A, et al: Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharmacol. 67:673–680. 2005. View Article : Google Scholar : PubMed/NCBI
10	Li HM, Feng QX, Dou KF, et al: Treatment of acute pancreatitis with ulinastatin: a report of 72 cases. Xi Bei Guo Fang Yi Xue Za Zhi. 23:183–185. 2002.[In Chinese].
11	Rongione AJ, Kusske AM, Kwan K, et al: Interleukin 10 reduces the severity of acute pancreatitis in rats. Gastroenterology. 112:960–967. 1997. View Article : Google Scholar : PubMed/NCBI
12	Balldin G, Borgström A, Genell S and Ohlsson K: The effect of peritoneal lavage and aprotinin in the treatment of severe acute pancreatitis. Res Exp Med (Berl). 183:203–213. 1983. View Article : Google Scholar : PubMed/NCBI
13	Ohlsson K and Tegner H: Experimental pancreatitis in the dog. Demonstration of trypsin in ascitic fluid, lymph and plasma. Scand J Gastroenterol. 8:129–133. 1973.PubMed/NCBI
14	Bhatia M, Wong FL, Cao Y, et al: Pathophysiology of acute pancreatitis. Pancreatology. 5:132–144. 2005. View Article : Google Scholar : PubMed/NCBI
15	Berling R, Borgström A and Ohlsson K: Peritoneal lavage with aprotinin in patients with severe acute pancreatitis. Effects on plasma and peritoneal levels of trypsin and leukocyte proteases and their major inhibitors. Int J Pancreatol. Int J Pancreatol. 24:9–17. 1998.
16	Dong Z, Petrov MS, Xu J, et al: Peritoneal lavage for severe acute pancreatitis: a systematic review of randomised trials. World J Surg. 34:2103–2108. 2010. View Article : Google Scholar : PubMed/NCBI
17	Hirano T and Manabe T: Human urinary trypsin inhibitor, urinastatin, prevents pancreatic injuries induced by pancreaticobiliary duct obstruction with cerulein stimulation and systemic hypotension in the rat. Arch Surg. Arch Surg. 128:1322–1329. 1993. View Article : Google Scholar : PubMed/NCBI
18	Wang G, Wen J, Wilbur RR, et al: The effect of somatostatin, ulinastatin and Salvia miltiorrhiza on severe acute pancreatitis treatment. Am J Med Sci. 346:371–376. 2013. View Article : Google Scholar : PubMed/NCBI
19	Wallner G, Solecki M, Ziemiakowicz R, et al: Morphological changes of the pancreas in course of acute pancreatitis during treatment with Ulinastatin. Pol Przegl Chir. 85:114–122. 2013.PubMed/NCBI
20	Keck T, Balcom JH, Antoniu BA, et al: Regional effects of nafamostat, a novel potent protease and complement inhibitor, on severe necrotizing pancreatitis. Surgery. 130:175–181. 2001. View Article : Google Scholar : PubMed/NCBI
21	Watanabe S: Acute pancreatitis: overview of medical aspects. Pancreas. 16:307–311. 1998. View Article : Google Scholar : PubMed/NCBI
22	Matsukawa H, Hara A, Ito T, et al: Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis - clinical effect of arterial injection of ulinastatin. Nihon Shokakibyo Gakkai Zasshi. Nihon Shokakibyo Gakkai Zasshi. 95:1229–1234. 1998.[In Japanese]. PubMed/NCBI
23	Botoi G and Andercou A: Early and prolonged peritoneal lavage with laparoscopy in severe acute pancreatitis. Chirurgia (Bucur). 104:49–53. 2009.[In Romanian]. PubMed/NCBI